


Application of Halogen Bond in Drug Discovery

Apr 2023



Introduction

Halogen bond (XB) is a highly directional and specific interaction driven by the σ -hole, a positively charged region on the hind side of X along the R–X bond axis that is caused by an anisotropy of electron density on the halogen (**Figure 1a**)¹. Halogen bond is formed between a covalently bonded halogen atom (XB donor) and a nucleophile (i.e., Lewis base; XB acceptor) (**Figure 1b**). In general, heavy halogens, such as -Cl, -Br and -I, can form halogen bonds while fluorine cannot².




Figure 1: 1a) The anisotropy of the electron density on the Halogen. The positive surface potential (including the σ -hole on the halogen) is colored in red, and the negative surface potential is colored in light blue. 1b) Typical Halogen bonds: one covalently bonded halogen atom and a nucleophile. R–X... acceptor angle is close to 180°.

In protein–ligand environments, halogen bonds can be formed between a halogenated ligand and any accessible Lewis base in the binding pocket, such as the backbone carbonyl oxygen, hydroxyls in serine, threonine, and tyrosine, carboxylate groups in aspartate and glutamate, sulfur in cysteine and methionine, nitrogen in histidine, and the π surface of phenylalanine, tyrosine, histidine, and tryptophan¹. One typical example is halogen atoms getting involved in the hinge region binding instead of the canonical hinge binders (**Figure 2**)¹.




Figure 2: 2a) Kinase Hinge binding through two chlorine atoms with the with backbone carbonyl oxygens; 2b) Kinase Canonical Hinge binding by Hydrogen bonds.

Halogen bond has attracted a lot of attention in drug discovery for hit-to-lead-to-candidate optimization aiming at improving drug-target binding affinity over the past twenty years. The improvement of potency ranges from several folds (**Figure 3a**)³ to many folds (**Figure 3b**)⁴.




Figure 3. Halogen bond can increase the potency several folds





Figure 4. Halogen bond can increase the potency many folds


✳ Synthesis of Aryl Halides

1) Substitution of diazonium groups in aromatic compounds by halo.




Substitution of diazonium groups in aromatic compounds by halo or cyano groups in the presence of cuprous salts (Sandmeyer reaction), copper powder and hydrochloric or hydrobromic acid (Gattermann reaction) or cupric salts (Körner-Contardi reaction).

Formation of diazonium fluoroborates by diazotization of aromatic amines in the presence of fluoroborates, followed by their thermal decomposition to aryl fluorides (Balz-Schiemann reaction):




2) Electrophilic addition of aromatic compounds




RSC Advances, 2022, 12, 7115 - 7119

3) Reaction of aryl lithium and active halide (Br₂, CBr₄, 1,2-dibromotetrafluoroethane, I₂, hexachloroethane, NFSI, etc).




4) Bromination of phenols




Organic Syntheses, Coll. 1973,5,142 ; 1969,49, 6

5) Halogen exchange reaction




Journal of the American Chemical Society, 1959, 81, 3984-9

6) Photoassisted Cristol-Firth-Hunsdiecker reaction




Journal of Organic Chemistry, 1979, 44, 3405-6


7) Decarboxylation halogenation




J. Am. Chem. Soc. 2017, 139, 11527–11536



J. Name., 2013, 00, 1-3




J. Org. Chem. 2009, 74, 8874–8877



Organic Letters, 2005, 7, 4753-4756


8) Ortho-iodination reaction of benzoic acid derivatives via directed ortho-palladation followed by metal–iodine exchange




US2013/5705

Chemistry - A European Journal, 2009, 15, .5956 - 5968


9) Halodeboronation of aryl boronic acids




J. Org. Chem. 2004, 69, 566-569



US20210130369




Organic Letters, 2019, 21, 2488-2492



- Ligand-free and base-free
- functional group tolerable
- Gram-scale reaction

Tetrahedron Letters, 2021, 64, 152738

10) Using aliphatic brominated compounds as starting materials



Bioorganic & Medicinal Chemistry, 2021, 52, 116522

Building Blocks Containing Halogen Bonds

PharmaBlock has conducted a systematic study of clinical and preclinical drug molecules, and our chemists continue to pay attention to the latest research, design and synthesize a large number of halogenated organic compounds, which can be used to explore structure-activity relationship (SAR) and structure-property relationship (SPR). We offer more than 10000 unique heterocyclic building blocks, ranging from grams to kilograms, most of which are in stock (**Figure 5**).









































 PB96960 2250241-78-0	 PB96962 736925-08-9	 PBTQ8038 1167055-29-9	 PB02015 912773-22-9	 PBN2011099 1211596-19-8	 PBU9076 2166662-14-0	 PB03331 876379-74-7
 PBN2011491 1019018-46-2	 PBN2011094 1101121-05-4	 PBYS1317 1416372-61-6	 PBN2011492 1273577-71-1	 PBN2011559 1363381-10-5	 PBZ2968 339528-39-1	 PB00536 749849-14-7
 PBJL1007 885520-67-2	 PB96133 1190313-03-1	 PBLJ2525 219508-19-7	 PB03844 944896-42-8	 PBT5245 916179-87-8	 PB01965 1190314-17-0	 PBN2011098 1356144-48-3
 PB08109 1534688-50-0	 PBGJ1118 1251023-52-5	 PBGJ2075 1243419-67-1	 PBN2011436 947248-68-2	 PB00327 947248-49-9	 PBUA586 1239647-60-9	 PBTQ8037 1167056-17-8
 PBU3248 1935186-93-8	 PBN20121668 799293-91-7	 PBN20120322 799293-85-9	 PB06713 1160995-23-2	 PBN2011123 1152475-42-7	 PBU2100 1020036-34-3	 PB03836 916420-30-9
 PBZ0828 1245644-68-1	 PBN2011438 1124382-72-4	 PBN20120429 676371-00-9	 PBU0934 910777-49-0	 PBUB234 N/A	 PBGC501 2831908-81-5	 PB05442 352328-87-1

Figure 5. Representative building blocks containing halogen bonds at PharmaBlock

References

- [1] Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology. Rainer Wilcken *et al.* *J. Med. Chem.* **2013**, *56*, 1363–1388.
- [2] Halogen Bond: Its Role beyond Drug–Target Binding Affinity for Drug Discovery and Development. Zhijian Xu *et al.* *J. Chem. Inf. Model.* **2014**, *54*, 69–78.
- [3] Design and Synthesis of highly Potent and Selective (2-arylcarbamoyl-phenoxy)-acetic acid Inhibitors of Aldose Reductase for Treatment of Chronic Diabetic Complications. Michael C. Van Zandt *et al.* *Bioorg. Med. Chem.*, **2004**, *12*, 5661-5675.
- [4] “Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery. Debora Chiodi and Yoshihiro Ishihara. *J. Med. Chem.* **2023**, *66*, 8, 5305-533
- [5] DABCO as a practical catalyst for aromatic halogenation with N-halosuccinimides. Xu, Haiyan *et al.* *RSC Advances*, **2022**, *12*, 7115 – 7119.
- [6] Synthesis of 2-BROMONAPHTHALENE, *Organic Syntheses, Coll.* **1973**, *5*, 142 ; **1969**, *49*, 6
- [7] Nitrogen mustard analogs of antimalarial drugs. Peck, Richard M. *et al.* *Journal of the American Chemical Society*, **1959**, *81*, 3984-9.
- [8] Photoassisted Cristol-Firth-Hunsdiecker reaction. Meyers, A. I.; Fleming, Michael P. *Journal of Organic Chemistry*, **1979**, *44*, 3405-6.
- [9] Transition-metal-free decarboxylative iodination: New routes for decarboxylative oxidative cross-couplings. Perry, Gregory J. P. *et al.* *Journal of the American Chemical Society*, **2017**, *139*, 11527-11536.
- [10] Halogen-Bonding in a New Family of tris(haloanilato)metallate(III) Magnetic Molecular Building Blocks, *J. Name.*, **2013**, *00*, 1-3
- [11] Bromodecarboxylation of Quinoline Salicylic Acids: Increasing the Diversity of Accessible Substituted Quinolines. Janz, Kristin; Kaila, Neelu. *Journal of Organic Chemistry*, **2009**, *74*, 8874-8877.
- [12] Pyrazolo[1,5-a]pyridines as p38 Kinase Inhibitors. Stevens, Kirk L. *et al.* *Organic Letters*, **2005**, *7*, 4753-4756
- [13] Total Synthesis of the Aspercyclides. Pospisil, Jiri; Mueller, Christoph; Fuerstner, Alois. *Chemistry - A European Journal*, **2009**, *15*, 5956-5968.
- [14] Facile synthesis of 2-bromo-3-fluorobenzonitrile: An application and study of the halodeboronation of arylboronic acids. Szumigala, Ronald H. Jr. *et al.* *Journal of Organic Chemistry*, **2004**, *69*, 566-569
- [15] US20210130369, 2021.
- [16] Mechanism of Cu-Catalyzed Aryl Boronic Acid Halodeboronation Using Electrophilic Halogen: Development of a Base-Catalyzed Iododeboronation for Radiolabeling Applications. Molloy, John J. *et al.* *Organic Letters*, **2019**, *21*, 2488-2492.
- [17] Direct bromodeboronation of arylboronic acids with CuBr₂ in water. Tang, Yan-Ling *et al.* *Tetrahedron Letters*, **2021**, *64*, 152738.
- [18] AMPK inhibitor BML-275 induces neuroprotection through decreasing cyt c and AIF expression after transient brain ischemia. Hu, Yue; Dong, Yao-Dong *et al.* *Bioorganic & Medicinal Chemistry*, **2021**, *52*, 116522.

Jul. 2023



本社

〒160-0022 東京都新宿区新宿5-5-3 建成新宿ビル

TEL:03-3354-4026 FAX:03-3352-2196

大阪支店

〒541-0044 大阪市中央区伏見町2-5-7 岡田伏見町ビル

TEL:06-6231-5444 FAX:06-6233-6540

E-mail: info@namiki-s.co.jp

URL: <http://www.namiki-s.co.jp>

